Full-Time

Senior Clinical Research Associate – Sr Cra

Posted on 5/16/2025

Corcept Therapeutics

Corcept Therapeutics

501-1,000 employees

develops cortisol-modulating therapies for Cushing's syndrome

Compensation Overview

$145k - $178k/yr

San Carlos, CA, USA

Hybrid

Hybrid role; on-site 3 days/week; travel up to 30% may be required.

Category
Biology & Biotech (2)
,
Required Skills
Google Cloud Platform
Requirements
  • Applicants must be currently authorized to work in the United States on a full-time basis.
Responsibilities
  • Serves as a crucial member of the project team for the quality execution of assigned clinical protocols according to Corcept’s SOPs, ICH/GCP, and corporate and departmental program goals
  • Supports the Study Lead as an integral member of a multifunctional team to ensure clinical study activities including study start-up, enrollment, maintenance, and closeout are executed appropriately
  • Participates in protocol development, tracking changes for future protocol amendments, and works with medical writing to create protocol amendments as needed
  • Oversees some aspects of study management and vendors to ensure high quality of data
  • Works with the in-house Clinical Trial Administrator to ensure the meeting agendas and meeting minutes are created, tracked, distributed, filed, and are accurate
  • Participates in the review of study designs from an operations perspective, and site implementation tactics
  • May support Study Lead in the review of CRO/Vendor RFPs and participate in bid defenses and review and comment on proposals for vendor selection
  • Supports Study Lead in the development of study timelines and budgets per the corporate and departmental goals and continuously strives to ensure timelines and deliverables are met within budget
  • Develops study processes in support of the protocol, develops workflow and resource plans to achieve interim goals; modifies according to study progress
  • Escalates concerns regarding timelines, milestones, resourcing, and any potential study execution issue to the Study Lead
  • Participates in the development of critical study documents such as informed consent form templates, site management, and monitoring tools
  • Participates in the development, distribution, review, and tracking of essential trial documents
  • Ensures essential documents are submitted to Regulatory for IND Updates and Amendments per the recommended timelines of the Study Lead
  • Participates in the review and negotiation of site budgets and contracts
  • Participates in the recruitment of potential Investigators suitable for a particular protocol
  • Conducts sponsor oversight visits and may conduct site qualification visits and site initiation visits
  • Participates in the development of and ensures compliance with the clinical monitoring plan; co-monitors as needed for staff training and quality assurance (QA) purposes
  • Contributes to the case report form (CRF) design process including content, form layout, and edit check review
  • Maintains a complete and updated regulatory file for each assigned site
  • Supports aspects of study management to ensure high quality of data
  • Liaises with chemistry, manufacturing, and controls (CMC) team to forecast and monitor overall drug supply and expiration to ensure adequate availability throughout the trial. May review site-specific accountability logs to ensure accuracy and report findings to Study Lead
  • Supports other study-wide activities such as external vendors, sample handling, drug re-supply, investigator payments, overall data quality, and overall central records quality
  • Serves as in-house contact for protocol-related process questions and reports in FAQs
  • Participates in the evaluation of clinical study reports for accuracy, safety, and/or efficacy trends; as necessary for medical monitor review and/or IDMC meetings
  • Exercises sound judgment to resolve or, as appropriate seek expert input on protocol and drug questions, safety, regulatory, and legal questions
  • Demonstrates excellent knowledge of ICH guidelines, FDA regulations, and company SOPs related to clinical studies and coaches junior staff
  • Contributes to the SOP review process and/or other Clinical Operations Initiatives
  • Ensures Trial Master File (TMF) is maintained throughout the study and helps with periodic TMF audits
  • Maintains a complete and updated regulatory file for each assigned site
  • Practices professionalism and integrity in all actions and relationships with Corcept management, supervisors, team members, and vendors. Demonstrates teamwork, cooperation, self-mastery, and flexibility to get the work done
  • Travel may be up to 30% occasionally
Desired Qualifications
  • Technical knowledge and experience managing most aspects of clinical studies
  • Experience in the pharmaceutical industry
  • Excellent knowledge of US and GCP/ICH regulations
  • Understanding of the clinical trials process, the application of SOPs, and medical terminology
  • Interpersonal, problem-solving, and organizational skills
  • Self-motivated and able to motivate others
  • Attention to detail and ability to prioritize tasks to meet critical deadlines
  • Ability to read and understand scientific literature
  • Excellent verbal and written communication
  • Organization and time management
  • Ability to develop and deliver compelling and concise presentations
  • Able to work effectively on project teams and independently
  • Strong proficiency in Microsoft Office and ability to utilize a wide range of computer applications and tools

Corcept Therapeutics develops and commercializes cortisol modulators to treat disorders caused by abnormal cortisol levels. Its main product, Korlym (mifepristone), blocks cortisol activity and is approved by the FDA for hypercortisolism in Cushing's syndrome; the company also works on additional cortisol-modulating treatments in its pipeline. The focus on specific cortisol modulation sets it apart, supported by ongoing R&D and education initiatives for healthcare professionals and patients. The company aims to improve outcomes for patients with Cushing's syndrome and other cortisol-related disorders by expanding access to effective therapies and advancing new treatments.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Menlo Park, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Lifyorli gained NCCN preferred status with over 200 physicians prescribing since March 2026.
  • 2026 revenue guidance raised to $950M–$1.05B after Q1 $164.9M sales beat expectations.
  • Pipeline expands relacorilant to endometrial, cervical, pancreatic, prostate cancers via BELLA trials.

What critics are saying

  • Teva launches generic Korlym after Federal Circuit invalidates patents, eroding 80% revenue.
  • Relacorilant Cushing's NDA rejected December 30, 2025 by FDA Complete Response Letter.
  • Securities class action over NDA misrepresentations settles by April 21, 2026 deadline.

What makes Corcept Therapeutics unique

  • Corcept pioneered cortisol modulation with Korlym approved in 2012 for Cushing's syndrome.
  • Lifyorli is first FDA-approved selective glucocorticoid receptor antagonist for ovarian cancer.
  • ROSELLA trial showed 4.1-month OS benefit in platinum-resistant ovarian cancer patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

6%

2 year growth

5%
Yahoo Finance
Apr 12th, 2026
Corcept Therapeutics price target slashed to $67 amid generic Korlym setback, FDA approves Lifyorli

Corcept Therapeutics is seeing divergent analyst views following legal and regulatory developments. H.C. Wainwright maintained its Buy rating but slashed its price target to $67 from $105, citing a court decision that removed the prospect of blocking Teva's generic Korlym. However, Wolfe Research upgraded the stock, viewing the risk-reward profile as more attractive at current valuations. The FDA approved Lifyorli (relacorilant) combined with nab-paclitaxel for platinum-resistant ovarian cancer, based on the ROSELLA trial showing a 35% reduction in death risk. Corcept also submitted a Marketing Authorisation Application to the European Medicines Agency for the same indication. The company issued 2026 revenue guidance of $900 million to $1 billion, whilst facing a securities class action lawsuit alleging it misled investors about FDA approval risks.

The Associated Press
Apr 10th, 2026
Lifyorli plus nab-paclitaxel cuts death risk by 35% in platinum-resistant ovarian cancer

Corcept Therapeutics presented final data from its pivotal Phase 3 ROSELLA trial at the Society of Gynecologic Oncology 2026 Annual Meeting, with simultaneous publication in The Lancet. The trial evaluated Lifyorli (relacorilant) combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer. The trial met its dual primary endpoints. Patients receiving Lifyorli plus nab-paclitaxel experienced a 35% reduction in death risk compared to nab-paclitaxel alone, with median overall survival of 16.0 months versus 11.9 months. Disease progression risk was reduced by 30%. Lifyorli, approved by the FDA in March 2026, is the first FDA-approved selective glucocorticoid receptor antagonist. The combination has been added to NCCN Clinical Practice Guidelines as a preferred regimen for platinum-resistant ovarian cancer. The trial enrolled 381 patients across multiple countries.

NewMediaWire
Mar 28th, 2026
Deadline is April 21, 2026 to lead in securities class action against Corcept Therapeutics, Inc. (NASDAQ: CORT) - contact Kaplan Fox.

Deadline is April 21, 2026 to lead in securities class action against Corcept Therapeutics, Inc. (NASDAQ: CORT) - contact Kaplan Fox. Mar. 28, 2026 6:30 AM ET Source: Kaplan Fox NEW YORK, NY - March 28, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. ("Corcept" or the "Company") (NASDAQ: CORT) on behalf of all persons or entities that purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the "Class Period"). If you are a Corcept investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than April 21, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. According to the complaint, "Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. One of its lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as "Cushing's syndrome"). The complaint further alleges that "Defendants' Class Period representations that the relacorilant NDA was supported by powerful evidence, that it was approaching approval, and that they had no concerns about the FDA's review were false. In truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result, there was a known material risk that Corcept's relacorilant NDA would not be approved." The complaint alleges that the "[t]he truth emerged on December 31, 2025, when Corcept revealed that the FDA had issued a Complete Response Letter... regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had 'concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.' The press release quoted Defendant Belanoff as stating that '[w]e are surprised and disappointed by this outcome.' As a result of this disclosure, the price of Corcept common stock declined by $35.40 per share, or 50.4%." WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this investigation, please contact: Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1501 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

Yahoo Finance
Mar 28th, 2026
Corcept Therapeutics gains 9% as FDA approves Lifyorli for ovarian cancer treatment

Corcept Therapeutics shares gained nearly 9% this week after receiving US Food and Drug Administration approval for Lifyorli, its leading drug candidate. The treatment was approved for use in combination with nab-paclitaxel to treat platinum-resistant fallopian tube, primary peritoneal and ovarian cancer in patients who previously received one to three systemic treatment regimes. Following the announcement on Wednesday, Wolfe Research analyst Kalpit Patel upgraded his recommendation from underperform to peerperform, though he expressed concerns about the company's Korlym drug weighing on growth potential. The approval demonstrates Corcept's cortisol-focused development approach can succeed beyond Cushing's syndrome treatment, giving the biotech a marketable product in the high-demand cancer segment.

The Associated Press
Mar 26th, 2026
Onco360 named national pharmacy partner for ovarian cancer treatment LIFYORLI

Onco360, the largest independent specialty pharmacy in the US, has been selected as the national pharmacy partner for LIFYORLI (relacorilant) by Corcept Therapeutics. LIFYORLI is indicated in combination with nab-paclitaxel for treating adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. LIFYORLI is a reversible glucocorticoid receptor antagonist. Its approval was based on the phase 3 ROSELLA study, which enrolled 381 patients and met its dual primary endpoints of progression-free and overall survival. Onco360, founded in 2003 and headquartered in Louisville, Kentucky, operates URAC- and ACHC-accredited oncology pharmacies nationwide, providing clinical support services for oncologists, patients and healthcare facilities.

INACTIVE